Developer docs
API playgroundTry for free, no card

Search company profiles

BathGenBio

Full company profile

uuid0003d9p

Namestring
BathGenBio
Legal namestring
Basgenbio Corporation
Websiteurl
basgenbio.com
Company typeenum
Private
Founded yearint
2018
Descriptiontext

BathGenBio (Basgenbio Corporation, 주식회사 바스젠바이오) is a Seoul-based AI drug discovery and genomic biomarker company founded in 2018 that provides clinico-omics data analytics to pharmaceutical companies, biotech firms, academic medical centers, and Korean government health agencies. The company operates three core proprietary platforms: COCD (Clinico-Omics Cohort Database), an integrated multi-omics data layer built around an exclusive license to the K-Biobank (156,000 Korean subjects with up to 18 years longitudinal follow-up) plus UK Biobank (500K+), TCGA (10K+), and ADNI (2K+), totaling 730,000+ subjects; DEEPCT (DEEP learning-based Clinical Trial), a drug effect simulation platform that applies Mendelian randomization causal inference plus deep learning to identify drug targets, drug repurposing opportunities, optimal drug combinations, and responder/non-responder biomarkers; and TLBM (Time-Labeled BioMarker), a time-aware biomarker discovery framework that integrates polygenic risk scores with longitudinal data to predict disease onset timing and age-specific risk.

Revenue is generated through three primary streams: (1) technology licensing and out-licensing of biomarkers and drug targets (e.g., gastric cancer TLBM licensed to Gencuric; five colorectal cancer targets transferred to Yungjin Pharmaceutical) with upfront fees, milestones, and royalties; (2) fee-for-service and co-development contracts with pharmaceutical companies including Celltrion (10 joint R&D projects over 5 years plus equity investment), Daewoong Pharmaceutical, Donga ST, Yungjin Pharmaceutical, Allico Pharmaceutical, and Samjin Pharmaceutical; and (3) non-dilutive Korean government R&D funding, most notably a ₩3.6 billion Deep-tech Challenge Project award over three years for a digital-twin androgenetic alopecia drug program, alongside the 2024 창업성장기술개발사업 디딤돌 bridge program. Go-to-market is enterprise sales-led through direct engagement at international partnering conferences (BIO USA, BIO Japan, Global IR @JPM, BIO KOREA BIX), supported by peer-reviewed publications in Nature Scientific Reports and the Journal of Investigative Dermatology. The company holds 13+ registered patents (including a PCT international filing for core TLBM technology), T-4 grade technology evaluation, and operates under dual co-CEO leadership (Il-Tae Jang, MD and Ho Kim) with a Vice President/CFO hired in 2021 to lead IPO preparation.

Short descriptiontext

BathGenBio is a Seoul-based AI drug discovery company that applies deep learning and Mendelian randomization to a 730,000+ subject multi-omics cohort database, selling biomarker licensing, drug target discovery, and co-development services to pharmaceutical and biotech companies in South Korea and internationally.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI drug discovery, genomic biomarker analysis, drug target identification, precision medicine platform, multi-omics data analytics
Industry2 codes
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
AI Drug Discovery Platform
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing & Transfer
TypeLicensing Royalties
Description

Out-licensing of biomarkers (e.g., gastric cancer TLBM to Gencuric), drug targets (e.g., 5 colorectal cancer targets to Yungjin Pharmaceutical), and AI platform results to pharmaceutical companies. Revenue includes upfront payments, milestone payments, and royalties.

basgenbio.com
2Co-development & Research Agreements
TypeProfessional Services
Description

Fee-for-service and co-development contracts with pharmaceutical companies for drug target discovery, drug repurposing, combination therapy optimization, and responder biomarker identification using DEEPCT and TLBM platforms.

koreabiomed.com
3Government R&D Grants
TypeSubscription Recurring
Description

Non-dilutive funding from Korean government programs including the Deep-tech Challenge Project (₩3.6B over 3 years), Startup Growth Technology Development (디딤돌), AI Voucher Support, and Global Technology Commercialization Support.

koreabiomed.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based service contracts negotiated with pharmaceutical and biotech partners
ModelOtherBilling cadenceMulti-year contract
Notes

No public pricing; contracts structured as milestone-based agreements with upfront fees, development payments, and downstream royalties.

koreabiomed.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

BathGenBio (BasgenBio) provides an AI-powered drug development platform built on its COCD (Clinico-Omics Cohort Database) integrating K-Biobank with global biobanks. Its DEEPCT platform simulates clinical trial outcomes for drug efficacy, adverse reactions, optimal combinations, and responder identification, while its TLBM (Time-Labeled BioMarker) platform discovers time-aware biomarkers for disease risk prediction. The company licenses biomarkers and drug targets to pharmaceutical and biotech partners and runs co-development research agreements.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 17x higher gastric cancer risk for high-risk group vs. normal group identified by TLBM biomarker BAS-GC-0001
+4 more records
Product overview1 text field

Basgenbio is a clinical multi-omics AI drug development company offering an integrated platform centered on three core products: COCD (Clinico-Omics Cohort Database) platform for data infrastructure, DEEPCT (DEEP learning-based Clinical Trial) for drug effect simulation, and TLBM (Time-Labeled BioMarker) for time-aware disease prediction. These are supplemented by specialized sub-products including Drug Combination analysis, Drug Response biomarker discovery, and Drug Repurposing services. The COCD platform serves as the data foundation, integrating K-Biobank (156K+ Korean subjects) with global biobanks, while DEEPCT and TLBM provide the analytical capabilities for pharmaceutical partnerships and biomarker out-licensing.

Product and service6 records
1COCD Platform (Clinico-Omics Cohort Database)
CategoryData Infrastructure
Description

Integrated cohort database platform combining K-Biobank (156,000 Korean subjects) with UK Biobank (500K+), TCGA (10K+), and ADNI (2K+) that incorporates genomics, clinical, lifestyle, and multi-omics data to support disease prediction, diagnosis, biomarker discovery, and drug target research.

2DEEPCT (DEEP learning-based Clinical Trial)
CategoryAI Drug Discovery Platform
Description

AI drug effect simulation platform that uses clinico-omics cohort data and Mendelian randomization methods to enable target discovery, drug-disease causal relationship identification, optimal drug combination recommendation, responder/non-responder biomarker identification, and drug repurposing without physical clinical trials.

3TLBM (Time-Labeled BioMarker)
CategoryBiomarker Discovery Platform
Description

Biomarker discovery platform incorporating time-factor data to predict disease onset timing and age-specific risk trajectories, integrating genetic risk scores with longitudinal health trajectory data to enable disease prediction, diagnosis, and prognosis.

4Drug Combination (COMBI FINDER)
CategoryDrug Combination Optimization
Description

Drug combination optimization tool analyzing prescription data, Mendelian randomization, network analysis, and AI to recommend optimal fixed-dose combination structures from 2-drug to N-drug combinations.

5Drug Response Biomarker
CategoryBiomarker Discovery
Description

Algorithm development service for predicting drug responders vs. non-responders, identifying biomarkers that classify treatment response for specific drug categories to enable personalized medicine.

6Drug Repurposing
Scale indicator12 records

Each record includes

Type, Value, Description, Source

Partnership20 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Exclusive technology transfer and co-development agreement signed May 2021 for Korean genomic cohort data (15.6万 subjects, ~₩77B R&D investment). BasgenBio acquired exclusive rights to K-Biobank and jointly conducts genomic cohort construction. ₩2.5B paid-in capital investment from Yonsei产学研合作단 in June 2021.

2Ewha Medical Center (이화의료원)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MOU signed July 2021 for research linking genomic cohort data with EMR records. Ewha provides additional genomic cohort data and clinical records to expand BasgenBio's multi-omics dataset.

basgenbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MOU signed August 2021 for AI-based precision medicine convergence platform development. Korea University contributes approximately 10,000 cancer patient genomic data — described as unique in Asia.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Comprehensive biomarker development partnership with equity investment signed May 2023. Plans 10 joint R&D projects over 5 years covering genomic analysis, biomarker discovery, target identification, candidate screening, and clinical trial design. Celltrion made a strategic equity investment alongside the partnership.

5Yungjin Pharmaceutical (영진약품)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Technology transfer agreement for 5 novel colorectal cancer targets and effective substances, signed September 2024. Also signed March 2024 MOU for KL1333 indication expansion (mitochondrial disease drug). Yungjin has a strategic interest in KL1333 (in-licensed from Abliva, entering Phase 2/3).

basgenbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Open innovation collaboration selected for 2024 Korea Civil Collaboration program. Project focuses on anticancer drug combination optimization and efficacy simulation using DEEPCT platform, with ₩50M government support. Jointly won Grand Prize in the demand-based category of the 2024 민관협력 오픈이노베이션 program.

7Donga ST (동아에스티)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Business collaboration agreement signed April 2024 for indication research of anticancer drug candidates using DEEPCT platform to identify and validate additional indications.

basgenbio.com
8Allico Pharmaceutical (알리코제약)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

MOU signed September 2022 for combination drug development. BasgenBio applies DEEPCT to identify optimal drug combinations; Allico validates and commercializes the combinations.

basgenbio.com
9Samjin Pharmaceutical (삼진제약)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

AI new drug development MOU signed November 2022 for target discovery and efficacy evaluation of new drug candidates using BasgenBio's genomic cohort data and AI platform.

basgenbio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

MOU signed March 2024 to leverage Korea's largest rheumatic arthritis cohort (since 2001) plus SLE cohort data (since 1998) for drug target discovery using DEEPCT in rheumatoid arthritis, SLE, and ankylosing spondylitis.

Strategic tierCoreTypeOEM/ Whitelabel/ Licensing Partner
Description

Technology transfer agreement signed September 2022 for gastric cancer TLBM biomarker. First commercial out-licensing of BasgenBio's time-labeled biomarker technology for molecular diagnostic product development.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Global licensing partnership for sarcopenia drug candidate KSB-10301. BasgenBio validated the target and drug effects using DEEPCT, demonstrating superiority over competing drugs. KSB-10301 entered Phase 2 clinical trial in November 2024.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Selected for Weconomy Startup Challenge 2024 as one of 15 promising startups from 187 applicants, collaborating with 8 large companies in Magok industrial complex including LG Sciencepark, Daewoong Pharmaceutical, and others.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

AI bio-bigdata commercialization MOU signed 2023 for peptide drug efficacy validation using BasgenBio's genomic cohort data and AI analysis platform.

15Hancomcarelink (한컴케어링크)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

AI bio-bigdata commercialization MOU signed 2023 for healthcare data collaboration.

basgenbio.com
16KT
Strategic tierMinorTypeOthers
Description

Selected for KT's Hyperscale AI Computing (HAC) GPU cloud support program. Received large-scale GPU infrastructure at no cost for AI model training and genomic data analysis, saving approximately ₩1 billion in infrastructure costs. Support extended to February 2024.

basgenbio.com
17Korea Government — Deep-tech Challenge Project
Strategic tierCoreTypeOthers
Description

Selected for Korea's Deep-tech Challenge Project receiving up to ₩3.6 billion (~$2.4M) in government R&D funding over 3 years for digital-twin androgenetic alopecia drug program. Collaborates with Yonsei University and Dankook University for clinical and omics dataset mining.

koreabiomed.com
18Korea Ministry of SMEs and Startups — 2024 창업성장기술개발사업
Strategic tierMinorTypeOthers
Description

Selected for '2024 3rd 디딤돌' Startup Growth Technology Development program. Receives up to ₩120 million in technology development funding over 1 year.

basgenbio.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

BasgenBio was admitted to SeoulBioHub startup cluster and received support from Invest Seoul for participation in global BIO conferences and IR activities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Long-standing research collaboration since 2018. Professor Ji Sun-ha has led cohort data collection since 2005. Joint research published in Korean Journal of Epidemiology (Epidemiology and Health) on bilirubin-ischemic stroke causal relationship.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Peers10 records
TypeDirect peer
Description

AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable to BasgenBio in using AI to accelerate pharma R&D, though Recursion focuses on phenotypic screening rather than genomic cohort analysis.

TypeDirect peer
Description

AI drug discovery platform using generative AI and multi-omics data for target identification and drug design. Directly comparable to BasgenBio's DEEPCT platform for AI-driven target discovery and drug repurposing.

TypeBroad incumbent
Description

Established computational chemistry and molecular simulation platform serving pharma R&D. Comparable as a pharma-facing AI/ML drug discovery company, but Schrödinger's focus is physics-based simulation rather than genomic cohort analysis.

TypeDirect peer
Description

AI-driven precision medicine company focused on patient selection and drug design. Directly comparable to BasgenBio's drug response biomarker and target discovery offerings for pharmaceutical partners.

TypeDirect peer
Description

Korean AI drug discovery company using proprietary AI workflows for target identification, lead optimization, and drug repurposing. Closest Korean peer to BasgenBio, operating in the same domestic pharma ecosystem with similar GTM motion.

TypeDirect peer
Description

Korean AI drug discovery company using deep learning for novel drug development and biomarker discovery. Comparable as a domestic peer in the Korean AI biotech space with pharma partnership model.

7Tempus Labs
TypeBroad incumbent
Description

Large-scale clinical and genomic data company enabling precision medicine. Comparable to BasgenBio's COCD platform in building multi-modal clinico-omics datasets, but Tempus operates at much larger scale in oncology-focused US market.

TypeEmerging player
Description

AI biotech company combining multi-omics data with federated learning for drug discovery and clinical trial optimization. Comparable in using AI on multi-omics cohorts to support pharma R&D decisions, with similar biomarker discovery positioning.

TypeEmerging player
Description

AI-driven drug discovery company combining quantum physics, AI, and cloud computing for pharmaceutical R&D. Comparable as an AI-platform-for-pharma peer, though XtalPi focuses on molecular design rather than genomic biomarker discovery.

TypeEmerging player
Description

Korean AI-driven drug discovery company focused on new drug candidate identification. Comparable as a Korean peer in AI drug discovery with similar pharmaceutical partnership business model.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers10 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

BathGenBio

AI Drug Discovery Platformbasgenbio.com

BathGenBio is a Seoul-based AI drug discovery company that applies deep learning and Mendelian randomization to a 730,000+ subject multi-omics cohort database, selling biomarker licensing, drug target discovery, and co-development services to pharmaceutical and biotech companies in South Korea and internationally.

What BathGenBio does

BathGenBio (Basgenbio Corporation, 주식회사 바스젠바이오) is a Seoul-based AI drug discovery and genomic biomarker company founded in 2018 that provides clinico-omics data analytics to pharmaceutical companies, biotech firms, academic medical centers, and Korean government health agencies. The company operates three core proprietary platforms: COCD (Clinico-Omics Cohort Database), an integrated multi-omics data layer built around an exclusive license to the K-Biobank (156,000 Korean subjects with up to 18 years longitudinal follow-up) plus UK Biobank (500K+), TCGA (10K+), and ADNI (2K+), totaling 730,000+ subjects; DEEPCT (DEEP learning-based Clinical Trial), a drug effect simulation platform that applies Mendelian randomization causal inference plus deep learning to identify drug targets, drug repurposing opportunities, optimal drug combinations, and responder/non-responder biomarkers; and TLBM (Time-Labeled BioMarker), a time-aware biomarker discovery framework that integrates polygenic risk scores with longitudinal data to predict disease onset timing and age-specific risk.

Revenue is generated through three primary streams: (1) technology licensing and out-licensing of biomarkers and drug targets (e.g., gastric cancer TLBM licensed to Gencuric; five colorectal cancer targets transferred to Yungjin Pharmaceutical) with upfront fees, milestones, and royalties; (2) fee-for-service and co-development contracts with pharmaceutical companies including Celltrion (10 joint R&D projects over 5 years plus equity investment), Daewoong Pharmaceutical, Donga ST, Yungjin Pharmaceutical, Allico Pharmaceutical, and Samjin Pharmaceutical; and (3) non-dilutive Korean government R&D funding, most notably a ₩3.6 billion Deep-tech Challenge Project award over three years for a digital-twin androgenetic alopecia drug program, alongside the 2024 창업성장기술개발사업 디딤돌 bridge program. Go-to-market is enterprise sales-led through direct engagement at international partnering conferences (BIO USA, BIO Japan, Global IR @JPM, BIO KOREA BIX), supported by peer-reviewed publications in Nature Scientific Reports and the Journal of Investigative Dermatology. The company holds 13+ registered patents (including a PCT international filing for core TLBM technology), T-4 grade technology evaluation, and operates under dual co-CEO leadership (Il-Tae Jang, MD and Ho Kim) with a Vice President/CFO hired in 2021 to lead IPO preparation.

BathGenBio firmographics

Firmographics
Name
BathGenBio
Legal name
Basgenbio Corporation
Website
https://basgenbio.com
Company type
Private
Founded year
2018
Operating status
Operating
Headcount range
11–50 employees
Short description
BathGenBio is a Seoul-based AI drug discovery company that applies deep learning and Mendelian randomization to a 730,000+ subject multi-omics cohort database, selling biomarker licensing, drug target discovery, and co-development services to pharmaceutical and biotech companies in South Korea and internationally.
Ownership category
akta.pro rank

BathGenBio industry classification

Industry
Product category
AI Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGANAI
Bioinformatics, Multi-Omics Data Analysis & Interpretation Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Specialty Lab Services (Genomics/Proteomics/Cellomics)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • AI drug discovery
  • Genomic biomarker analysis
  • Drug target identification
  • Precision medicine platform
  • Multi-omics data analytics

Where BathGenBio is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

BathGenBio business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing & Transfer: Out-licensing of biomarkers (e.g., gastric cancer TLBM to Gencuric), drug targets (e.g., 5 colorectal cancer targets to Yungjin Pharmaceutical), and AI platform results to pharmaceutical companies. Revenue includes upfront payments, milestone payments, and royalties.
  2. Co-development & Research Agreements: Fee-for-service and co-development contracts with pharmaceutical companies for drug target discovery, drug repurposing, combination therapy optimization, and responder biomarker identification using DEEPCT and TLBM platforms.
  3. Government R&D Grants: Non-dilutive funding from Korean government programs including the Deep-tech Challenge Project (₩3.6B over 3 years), Startup Growth Technology Development (디딤돌), AI Voucher Support, and Global Technology Commercialization Support.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based service contracts negotiated with pharmaceutical and biotech partners

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

BathGenBio product offering

Product offering

Core offering

BathGenBio (BasgenBio) provides an AI-powered drug development platform built on its COCD (Clinico-Omics Cohort Database) integrating K-Biobank with global biobanks. Its DEEPCT platform simulates clinical trial outcomes for drug efficacy, adverse reactions, optimal combinations, and responder identification, while its TLBM (Time-Labeled BioMarker) platform discovers time-aware biomarkers for disease risk prediction. The company licenses biomarkers and drug targets to pharmaceutical and biotech partners and runs co-development research agreements.

Product overview

Basgenbio is a clinical multi-omics AI drug development company offering an integrated platform centered on three core products: COCD (Clinico-Omics Cohort Database) platform for data infrastructure, DEEPCT (DEEP learning-based Clinical Trial) for drug effect simulation, and TLBM (Time-Labeled BioMarker) for time-aware disease prediction. These are supplemented by specialized sub-products including Drug Combination analysis, Drug Response biomarker discovery, and Drug Repurposing services. The COCD platform serves as the data foundation, integrating K-Biobank (156K+ Korean subjects) with global biobanks, while DEEPCT and TLBM provide the analytical capabilities for pharmaceutical partnerships and biomarker out-licensing.

Differentiator

Problem solved

Functional benefit

Products and services

  • COCD Platform (Clinico-Omics Cohort Database) Integrated cohort database platform combining K-Biobank (156,000 Korean subjects) with UK Biobank (500K+), TCGA (10K+), and ADNI (2K+) that incorporates genomics, clinical, lifestyle, and multi-omics data to support disease prediction, diagnosis, biomarker discovery, and drug target research.
  • DEEPCT (DEEP learning-based Clinical Trial) AI drug effect simulation platform that uses clinico-omics cohort data and Mendelian randomization methods to enable target discovery, drug-disease causal relationship identification, optimal drug combination recommendation, responder/non-responder biomarker identification, and drug repurposing without physical clinical trials.
  • TLBM (Time-Labeled BioMarker) Biomarker discovery platform incorporating time-factor data to predict disease onset timing and age-specific risk trajectories, integrating genetic risk scores with longitudinal health trajectory data to enable disease prediction, diagnosis, and prognosis.
  • Drug Combination (COMBI FINDER) Drug combination optimization tool analyzing prescription data, Mendelian randomization, network analysis, and AI to recommend optimal fixed-dose combination structures from 2-drug to N-drug combinations.
  • Drug Response Biomarker Algorithm development service for predicting drug responders vs. non-responders, identifying biomarkers that classify treatment response for specific drug categories to enable personalized medicine.
  • Drug Repurposing

Quantifiable outcome

  • 17x higher gastric cancer risk for high-risk group vs. normal group identified by TLBM biomarker BAS-GC-0001
  • +4 more outcomes

Companies that use BathGenBio

Customer profile

Named customers10 records

Segments3 records

Ideal customer profiles2 records

BathGenBio technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature5 records

BathGenBio partnerships and signals

Strategic signal

Partnerships

20 partnerships are on record, tiered core and minor.

  • Yonsei Medical Center (연세의료원)coreStrategic or Co-development PartnerExclusive technology transfer and co-development agreement signed May 2021 for Korean genomic cohort data (15.6万 subjects, ~₩77B R&D investment). BasgenBio acquired exclusive rights to K-Biobank and jointly conducts genomic cohort construction. ₩2.5B paid-in capital investment from Yonsei产学研合作단 in June 2021.
  • Ewha Medical Center (이화의료원)coreStrategic or Co-development PartnerMOU signed July 2021 for research linking genomic cohort data with EMR records. Ewha provides additional genomic cohort data and clinical records to expand BasgenBio's multi-omics dataset.
  • Korea University Medical Center (고려대학교의료원)coreStrategic or Co-development PartnerMOU signed August 2021 for AI-based precision medicine convergence platform development. Korea University contributes approximately 10,000 cancer patient genomic data — described as unique in Asia.
  • CelltrioncoreStrategic or Co-development PartnerComprehensive biomarker development partnership with equity investment signed May 2023. Plans 10 joint R&D projects over 5 years covering genomic analysis, biomarker discovery, target identification, candidate screening, and clinical trial design. Celltrion made a strategic equity investment alongside the partnership.
  • Yungjin Pharmaceutical (영진약품)coreStrategic or Co-development PartnerTechnology transfer agreement for 5 novel colorectal cancer targets and effective substances, signed September 2024. Also signed March 2024 MOU for KL1333 indication expansion (mitochondrial disease drug). Yungjin has a strategic interest in KL1333 (in-licensed from Abliva, entering Phase 2/3).
  • Daewoong Pharmaceutical (대웅제약)coreStrategic or Co-development PartnerOpen innovation collaboration selected for 2024 Korea Civil Collaboration program. Project focuses on anticancer drug combination optimization and efficacy simulation using DEEPCT platform, with ₩50M government support. Jointly won Grand Prize in the demand-based category of the 2024 민관협력 오픈이노베이션 program.
  • Donga ST (동아에스티)minorStrategic or Co-development PartnerBusiness collaboration agreement signed April 2024 for indication research of anticancer drug candidates using DEEPCT platform to identify and validate additional indications.
  • Allico Pharmaceutical (알리코제약)minorStrategic or Co-development PartnerMOU signed September 2022 for combination drug development. BasgenBio applies DEEPCT to identify optimal drug combinations; Allico validates and commercializes the combinations.
  • Samjin Pharmaceutical (삼진제약)minorStrategic or Co-development PartnerAI new drug development MOU signed November 2022 for target discovery and efficacy evaluation of new drug candidates using BasgenBio's genomic cohort data and AI platform.
  • Hanyang University Rheumatism Research Institute (한양대학교류마티즘연구소)coreStrategic or Co-development PartnerMOU signed March 2024 to leverage Korea's largest rheumatic arthritis cohort (since 2001) plus SLE cohort data (since 1998) for drug target discovery using DEEPCT in rheumatoid arthritis, SLE, and ankylosing spondylitis.
  • Gencuric (젠큐릭스)coreOEM/ Whitelabel/ Licensing PartnerTechnology transfer agreement signed September 2022 for gastric cancer TLBM biomarker. First commercial out-licensing of BasgenBio's time-labeled biomarker technology for molecular diagnostic product development.
  • KSB Tugen (케이에스비튜젠)minorStrategic or Co-development PartnerGlobal licensing partnership for sarcopenia drug candidate KSB-10301. BasgenBio validated the target and drug effects using DEEPCT, demonstrating superiority over competing drugs. KSB-10301 entered Phase 2 clinical trial in November 2024.
  • Seoul Metropolitan Government / SBA (서울산업진흥원)minorGTM or Marketing PartnerSelected for Weconomy Startup Challenge 2024 as one of 15 promising startups from 187 applicants, collaborating with 8 large companies in Magok industrial complex including LG Sciencepark, Daewoong Pharmaceutical, and others.
  • 3-BIGS (쓰리빅스)minorStrategic or Co-development PartnerAI bio-bigdata commercialization MOU signed 2023 for peptide drug efficacy validation using BasgenBio's genomic cohort data and AI analysis platform.
  • Hancomcarelink (한컴케어링크)minorStrategic or Co-development PartnerAI bio-bigdata commercialization MOU signed 2023 for healthcare data collaboration.
  • KTminorOthersSelected for KT's Hyperscale AI Computing (HAC) GPU cloud support program. Received large-scale GPU infrastructure at no cost for AI model training and genomic data analysis, saving approximately ₩1 billion in infrastructure costs. Support extended to February 2024.
  • Korea Government — Deep-tech Challenge ProjectcoreOthersSelected for Korea's Deep-tech Challenge Project receiving up to ₩3.6 billion (~$2.4M) in government R&D funding over 3 years for digital-twin androgenetic alopecia drug program. Collaborates with Yonsei University and Dankook University for clinical and omics dataset mining.
  • Korea Ministry of SMEs and Startups — 2024 창업성장기술개발사업minorOthersSelected for '2024 3rd 디딤돌' Startup Growth Technology Development program. Receives up to ₩120 million in technology development funding over 1 year.
  • SeoulBioHub / Invest Seoul (서울바이오허브/인베스트서울)minorGTM or Marketing PartnerBasgenBio was admitted to SeoulBioHub startup cluster and received support from Invest Seoul for participation in global BIO conferences and IR activities.
  • Yonsei University Graduate School of Public Health (연세대학교 보건대학원)coreStrategic or Co-development PartnerLong-standing research collaboration since 2018. Professor Ji Sun-ha has led cohort data collection since 2005. Joint research published in Korean Journal of Epidemiology (Epidemiology and Health) on bilirubin-ischemic stroke causal relationship.

Scale indicators12 records

Recent moves7 records

BathGenBio competitors and assessment

Company assessment

Direct peers

  • Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning. Comparable to BasgenBio in using AI to accelerate pharma R&D, though Recursion focuses on phenotypic screening rather than genomic cohort analysis.
  • Insilico Medicine: AI drug discovery platform using generative AI and multi-omics data for target identification and drug design. Directly comparable to BasgenBio's DEEPCT platform for AI-driven target discovery and drug repurposing.
  • Exscientia: AI-driven precision medicine company focused on patient selection and drug design. Directly comparable to BasgenBio's drug response biomarker and target discovery offerings for pharmaceutical partners.
  • Standigm: Korean AI drug discovery company using proprietary AI workflows for target identification, lead optimization, and drug repurposing. Closest Korean peer to BasgenBio, operating in the same domestic pharma ecosystem with similar GTM motion.
  • Syntekabio: Korean AI drug discovery company using deep learning for novel drug development and biomarker discovery. Comparable as a domestic peer in the Korean AI biotech space with pharma partnership model.

Broad incumbents

  • Schrödinger: Established computational chemistry and molecular simulation platform serving pharma R&D. Comparable as a pharma-facing AI/ML drug discovery company, but Schrödinger's focus is physics-based simulation rather than genomic cohort analysis.
  • Tempus Labs: Large-scale clinical and genomic data company enabling precision medicine. Comparable to BasgenBio's COCD platform in building multi-modal clinico-omics datasets, but Tempus operates at much larger scale in oncology-focused US market.

Emerging players

  • Owkin: AI biotech company combining multi-omics data with federated learning for drug discovery and clinical trial optimization. Comparable in using AI on multi-omics cohorts to support pharma R&D decisions, with similar biomarker discovery positioning.
  • XtalPi: AI-driven drug discovery company combining quantum physics, AI, and cloud computing for pharmaceutical R&D. Comparable as an AI-platform-for-pharma peer, though XtalPi focuses on molecular design rather than genomic biomarker discovery.
  • Arontier: Korean AI-driven drug discovery company focused on new drug candidate identification. Comparable as a Korean peer in AI drug discovery with similar pharmaceutical partnership business model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

BathGenBio social profiles

Digital presence

BathGenBio financial estimates

Financial estimate

Revenue estimate

Valuation estimate

BathGenBio leadership team

Management profile

Number of profiles

Profiles6 records

BathGenBio funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

BathGenBio M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about BathGenBio

What does BathGenBio do?

BathGenBio (BasgenBio) provides an AI-powered drug development platform built on its COCD (Clinico-Omics Cohort Database) integrating K-Biobank with global biobanks. Its DEEPCT platform simulates clinical trial outcomes for drug efficacy, adverse reactions, optimal combinations, and responder identification, while its TLBM (Time-Labeled BioMarker) platform discovers time-aware biomarkers for disease risk prediction. The company licenses biomarkers and drug targets to pharmaceutical and biotech partners and runs co-development research agreements.

Is BathGenBio a public or private company?

BathGenBio is a private company. It is classified as venture growth investor backed and is currently operating.

When was BathGenBio founded?

BathGenBio was founded in 2018. It employs 11 to 50 people.

Where is BathGenBio based?

BathGenBio is headquartered in Seoul, South Korea, in the Asia region.

How does BathGenBio make money?

Three revenue lines are on record. Technology Licensing & Transfer is the primary driver. The others are co-development & Research Agreements and government R&D Grants.

Who are BathGenBio's main competitors?

Direct peers on record are Recursion Pharmaceuticals, Insilico Medicine, Exscientia, Standigm and Syntekabio. Broad incumbents are Schrödinger and Tempus Labs. Emerging players are Owkin, XtalPi and Arontier.

Does BathGenBio have an API?

No public API is recorded for BathGenBio.

What industry is BathGenBio in?

BathGenBio's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGANAI, Bioinformatics, Multi-Omics Data Analysis & Interpretation Services, with a secondary code of HLAIALAF, Translational Medicine & Biomarkers. Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals